Evidence map›Paper›PMID 31273781›Full record

ArticleJournal of neurochemistry2019

Aspirin up-regulates suppressor of cytokine signaling 3 in glial cells via PPARα.

Sudipta Chakrabarti, Avik Roy, Tim Prorok, Dhruv Patel, Sridevi Dasarathi, Kalipada Pahan

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Activation of PPARα Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sudipta ChakrabartiDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
Avik RoyDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
Tim ProrokDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
Dhruv PatelDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-5438-1051
Sridevi DasarathiDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
Kalipada PahanDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.ORCID 0000-0001-6048-9598
Rush University Medical Center · US

Funding

Characterizing novel hippocampal drugs for Alzheimer's diseaseR01AG050431 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2016 to 2020
$2.1M
Aspirin, PPAR and EAEI01BX002174 · VA · JESSE BROWN VA MEDICAL CENTER · PI PAHAN, KALIPADA · 2013 to 2016
–
BLRD VA I01 BX002174NIA NIH HHS R01 AG050431
6 · The paper itself

Abstract

Neuroinflammation is being recognized as a hallmark of different neurodegenerative disorders, including Alzheimer's disease. Suppressor of cytokine signaling 3 (SOCS3) is an anti-inflammatory molecule, which is known to inhibit cytokine signaling and inflammatory gene expression in different cells. However, the pathways by which SOCS3 could be up-regulated in brain cells are poorly understood. Aspirin is a widely available pain reliever that is showing promise beyond its known pain-relieving capacity. This study underlines the importance of aspirin in upregulating SOCS3 in astrocytes and microglia. Aspirin increased the expression of Socs3 mRNA and protein in mouse astrocytes and BV-2 microglial cells in both a time- and dose-dependent manner. While investigating the mechanism, we found that Socs3 gene promoter harbors peroxisome proliferator response element and that aspirin up-regulated SOCS3 in astrocytes isolated from PPARβ (-/-), but not PPARα (-/-), mice. Accordingly, aspirin increased SOCS3 in vivo in the cortex of wild type and PPARβ (-/-), but not PPARα (-/-), mice. Similarly, aspirin treatment increased astroglial and microglial SOCS3 in the cortex of FAD5X, but not FAD5X/PPARα (-/-), mice. Finally, recruitment of PPARα by aspirin to the proximal, but not distal, peroxisome proliferator response element of the Socs3 promoter suggests that aspirin increases the transcription of Socs3 gene via PPARα. This study describes a novel property of aspirin in elevating SOCS3 in glial cells via PPARα and suggests that aspirin may be further considered for therapeutic application in neuroinflammatory and neurodegenerative disorders.

Indexed as

Alzheimer DiseaseAnimalsAnti-Inflammatory Agents, Non-SteroidalAspirinFemaleMaleMiceMice, Inbred C57BLNeurogliaPPAR alphaSignal TransductionSuppressor of Cytokine Signaling 3 ProteinUp-RegulationAnti-Inflammatory Agents, Non-SteroidalAspirinPPAR alphaSocs3 protein, mouseSuppressor of Cytokine Signaling 3 ProteinAspirinFAD5X modelGlial cellsPPARαSOCS3

Identifiers

PMID31273781
PMCPMC6788957
OpenAlexW2956094899

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.